Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's (NOVOb.CO) , opens new tab Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the ...
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
Patients using Novo Nordisk’s NVO NONOF obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on Tuesday.
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...
The rapid rise of weight loss drugs Wegovy and Mounjaro is generating a host of new product lines as companies hope to land ...
Medicare just revised its guidelines to include coverage of Wegovy for patients with cardiovascular complications.
The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs analysts said in a research note.
Structure Therapeutics (NASDAQ: GPCR) might have something cooking that could one day unseat the likes of Novo Nordisk's (NYSE: NVO) Ozempic, a drug for type 2 diabetes, as well as its drug Wegovy, ...